By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

biopharma beat
BioPharma Beat: We Want Healthcare at Any Price – Until We Have It
CBO: Private Insurers Better at Expenditure Growth Control than Medicare, Medicaid
Who’s Paying the Chargemaster Rate? Not Just the Uninsured
Crowd-Sourcing in Clinical Development
UW Medicine’s Journey to Become an Accountable Care Organization

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

close up of hands holding baby feet
What to Record After a Preventable Birth Injury
Health care
March 14, 2026
Person Stressed Out in Courtroom
How Legal Challenges Can Affect Health and Wellness Journeys
Policy & Law
March 14, 2026
high-risk mdical case
Countdown To Care: What Happens In The 48 Hours Before A High-Risk Medical Case
Health Infographics
March 12, 2026
healthcare facilities
Behind The Cabinets: Why Secure Storage Matters In Modern Healthcare Facilities
Global Healthcare Infographics
March 12, 2026

You Might also Like

Top Ten Medical Innovations: Cleveland Clinic Summit Takeaway

October 18, 2011
medical school
BusinessMedical Education

First U.S. Insurer to Build Medical School

April 14, 2016
2014 health insurance premiums
Health ReformPolicy & Law

Are You Braced for 2014 Insurance Premiums? Will You Pay More or Less?

August 16, 2013

Managing The Nursing Shortage: 3 Short Term Solutions

March 15, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?